FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892560321> ?p ?o ?g. }

• W2892560321 endingPage "553" @default.
• W2892560321 startingPage "545" @default.
• W2892560321 abstract "Background and AimsColorectal cancer (CRC) is largely preventable with routine screening and surveillance colonoscopy; however, interval cancers arising from precancerous lesions missed by standard colonoscopy still occur. An increased adenoma detection rate (ADR) has been found to be inversely associated with interval cancers. The G-EYE device includes a reusable balloon integrated at the distal tip of a standard colonoscope, which flattens haustral folds, centralizes the colonoscope’s optics, and reduces bowel slippage. The insufflated balloon also aims to enhance visualization of the colon during withdrawal, thereby increasing the ADR.MethodsIn this randomized, controlled, international, multicenter study (11 centers), patients (aged ≥50 years) referred to colonoscopy for screening, surveillance, or changes in bowel habits were randomized to undergo either balloon-assisted colonoscopy by using an insufflated balloon during withdrawal or standard high-definition colonoscopy. The primary endpoint was the ADR.ResultsOne thousand patients were enrolled between May 2014 and September 2016 to undergo colonoscopy by experienced endoscopists; 803 were finally analyzed (standard colonoscopy n = 396; balloon-assisted colonoscopy n = 407). Baseline parameters were similar in both groups. Balloon-assisted colonoscopy provided a 48.0% ADR compared with 37.5% in the standard colonoscopy group (28% increase; P = .0027). Additionally, balloon-assisted colonoscopy provided for a significant increase in detection of advanced (P = .0033) flat adenomas (P < .0001) and sessile serrated adenomas/polyps (P = .0026).ConclusionBalloon-assisted colonoscopy yielded a higher ADR and increased the detection of advanced, flat, and sessile serrated adenomas/polyps when compared with standard colonoscopy. Improved detection by the G-EYE device could impact the quality of CRC screening by reducing miss rates and consequently reducing interval cancer incidence. (Clinical trial registration number: NCT01917513.) Colorectal cancer (CRC) is largely preventable with routine screening and surveillance colonoscopy; however, interval cancers arising from precancerous lesions missed by standard colonoscopy still occur. An increased adenoma detection rate (ADR) has been found to be inversely associated with interval cancers. The G-EYE device includes a reusable balloon integrated at the distal tip of a standard colonoscope, which flattens haustral folds, centralizes the colonoscope’s optics, and reduces bowel slippage. The insufflated balloon also aims to enhance visualization of the colon during withdrawal, thereby increasing the ADR. In this randomized, controlled, international, multicenter study (11 centers), patients (aged ≥50 years) referred to colonoscopy for screening, surveillance, or changes in bowel habits were randomized to undergo either balloon-assisted colonoscopy by using an insufflated balloon during withdrawal or standard high-definition colonoscopy. The primary endpoint was the ADR. One thousand patients were enrolled between May 2014 and September 2016 to undergo colonoscopy by experienced endoscopists; 803 were finally analyzed (standard colonoscopy n = 396; balloon-assisted colonoscopy n = 407). Baseline parameters were similar in both groups. Balloon-assisted colonoscopy provided a 48.0% ADR compared with 37.5% in the standard colonoscopy group (28% increase; P = .0027). Additionally, balloon-assisted colonoscopy provided for a significant increase in detection of advanced (P = .0033) flat adenomas (P < .0001) and sessile serrated adenomas/polyps (P = .0026). Balloon-assisted colonoscopy yielded a higher ADR and increased the detection of advanced, flat, and sessile serrated adenomas/polyps when compared with standard colonoscopy. Improved detection by the G-EYE device could impact the quality of CRC screening by reducing miss rates and consequently reducing interval cancer incidence. (Clinical trial registration number: NCT01917513.)" @default.
• W2892560321 created "2018-10-05" @default.
• W2892560321 creator A5001995991 @default.
• W2892560321 creator A5002485660 @default.
• W2892560321 creator A5003524553 @default.
• W2892560321 creator A5005486551 @default.
• W2892560321 creator A5010191776 @default.
• W2892560321 creator A5012353557 @default.
• W2892560321 creator A5013283781 @default.
• W2892560321 creator A5016294618 @default.
• W2892560321 creator A5020104528 @default.
• W2892560321 creator A5020701812 @default.
• W2892560321 creator A5021580115 @default.
• W2892560321 creator A5021837247 @default.
• W2892560321 creator A5024999099 @default.
• W2892560321 creator A5025111289 @default.
• W2892560321 creator A5028681615 @default.
• W2892560321 creator A5034469826 @default.
• W2892560321 creator A5034489934 @default.
• W2892560321 creator A5035705434 @default.
• W2892560321 creator A5036334249 @default.
• W2892560321 creator A5040485487 @default.
• W2892560321 creator A5042563389 @default.
• W2892560321 creator A5043293133 @default.
• W2892560321 creator A5047980989 @default.
• W2892560321 creator A5049241638 @default.
• W2892560321 creator A5052683471 @default.
• W2892560321 creator A5053444208 @default.
• W2892560321 creator A5054887040 @default.
• W2892560321 creator A5055196330 @default.
• W2892560321 creator A5055818241 @default.
• W2892560321 creator A5060021921 @default.
• W2892560321 creator A5060174925 @default.
• W2892560321 creator A5060915537 @default.
• W2892560321 creator A5061838629 @default.
• W2892560321 creator A5062521731 @default.
• W2892560321 creator A5062976501 @default.
• W2892560321 creator A5063543897 @default.
• W2892560321 creator A5068933841 @default.
• W2892560321 creator A5072891313 @default.
• W2892560321 creator A5074114867 @default.
• W2892560321 creator A5074268246 @default.
• W2892560321 creator A5074279497 @default.
• W2892560321 creator A5077217613 @default.
• W2892560321 creator A5078835717 @default.
• W2892560321 creator A5079705062 @default.
• W2892560321 creator A5079762459 @default.
• W2892560321 creator A5084344124 @default.
• W2892560321 creator A5089291330 @default.
• W2892560321 creator A5089803075 @default.
• W2892560321 creator A5090950342 @default.
• W2892560321 creator A5091661010 @default.
• W2892560321 date "2019-03-01" @default.
• W2892560321 modified "2023-10-16" @default.
• W2892560321 title "G-EYE colonoscopy is superior to standard colonoscopy for increasing adenoma detection rate: an international randomized controlled trial (with videos)" @default.
• W2892560321 cites W1974643789 @default.
• W2892560321 cites W1979613975 @default.
• W2892560321 cites W1993624105 @default.
• W2892560321 cites W1999336059 @default.
• W2892560321 cites W2005921914 @default.
• W2892560321 cites W2007309073 @default.
• W2892560321 cites W2018247165 @default.
• W2892560321 cites W2019490106 @default.
• W2892560321 cites W2026791416 @default.
• W2892560321 cites W2032059652 @default.
• W2892560321 cites W2043374703 @default.
• W2892560321 cites W2050696607 @default.
• W2892560321 cites W2054367831 @default.
• W2892560321 cites W2061619398 @default.
• W2892560321 cites W2063979222 @default.
• W2892560321 cites W2100618270 @default.
• W2892560321 cites W2111147183 @default.
• W2892560321 cites W2116402528 @default.
• W2892560321 cites W2117920692 @default.
• W2892560321 cites W2124755543 @default.
• W2892560321 cites W2124944441 @default.
• W2892560321 cites W2128379001 @default.
• W2892560321 cites W2130931735 @default.
• W2892560321 cites W2140876736 @default.
• W2892560321 cites W2143929290 @default.
• W2892560321 cites W2151255896 @default.
• W2892560321 cites W2158155001 @default.
• W2892560321 cites W2165188436 @default.
• W2892560321 cites W2236349172 @default.
• W2892560321 cites W2256100814 @default.
• W2892560321 cites W2313871714 @default.
• W2892560321 cites W2334144750 @default.
• W2892560321 cites W2341043851 @default.
• W2892560321 cites W2476059758 @default.
• W2892560321 cites W2510086083 @default.
• W2892560321 cites W2568763568 @default.
• W2892560321 cites W2619143830 @default.
• W2892560321 cites W2626993054 @default.
• W2892560321 cites W4242498330 @default.
• W2892560321 cites W955507656 @default.
• W2892560321 doi "https://doi.org/10.1016/j.gie.2018.09.028" @default.
• W2892560321 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30273591" @default.
• W2892560321 hasPublicationYear "2019" @default.

• next